Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy

Paediatric Anaesthesia

Volumn 26, Issue 12, 2016, Pages 1126-1135

  Tan, Lena ^a   Taylor, Elsa ^a   Hannam, Jacqueline A ^b   Salkeld, Lesley ^a   Salman, Sam ^c   Anderson, Brian J ^a,b  

^a STARSHIP CHILDREN S HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

anesthesia; nonsteroidal anti inflammatory drug; pain; pharmacodynamics; pharmacokinetics; tonsillectomy adenoidectomy

Indexed keywords

FENTANYL; MORPHINE; PARECOXIB; TRAMADOL; VALDECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ISOXAZOLE DERIVATIVE;

ADENOIDECTOMY; ANALGESIA; ARTICLE; BIOEQUIVALENCE; CHILD; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG USE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL DISCHARGE; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; NONLINEAR SYSTEM; PAIN ASSESSMENT; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TONSILLECTOMY; WALKING; ADOLESCENT; PAIN, POSTOPERATIVE; PRESCHOOL CHILD; PROCEDURES; TREATMENT OUTCOME;

ADENOIDECTOMY; ADOLESCENT; ANALGESIA; CHILD; CHILD, PRESCHOOL; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; ISOXAZOLES; MALE; PAIN, POSTOPERATIVE; TONSILLECTOMY; TREATMENT OUTCOME;

EID: 84995572312     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/pan.13009     Document Type: Article

References (39)

1. Hullett B, Salman S, O'Halloran SJ et al. Development of a population pharmacokinetic model for parecoxib and its active metabolite valdecoxib after parenteral parecoxib administration in children. Anesthesiology 2012; 116: 1124–1133.
2. Bu X, Yang L, Zuo Y. Efficacy and safety of perioperative parecoxib for acute postoperative pain treatment in children: a meta-analysis. Front Med 2015; 9: 496–507.
3. ® (parecoxib sodium) Data Sheet. Wellington: New Zealand Medicines and Medical Devices Safety Authority, 2014:1–26.
4. Korpela R, Olkkola KT. Pharmacokinetics of intravenous diclofenac sodium in children. Eur J Clin Pharmacol 1990; 38: 293–295.
5. Dsida RM, Wheeler M, Birmingham PK et al. Age-stratified pharmacokinetics of ketorolac tromethamine in pediatric surgical patients. Anesth Analg 2002; 94: 266–270.
6. Forrest JB, Heitlinger EL, Revell S. Ketorolac for postoperative pain management in children. Drug Saf 1997; 16: 309–329.
7. Hicks CL, von Baeyer CL, Spafford PA et al. The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement. Pain 2001; 93: 173–183.
8. Kataria BK, Ved SA, Nicodemus HF et al. The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology 1994; 80: 104–122.
9. Beal ST. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481–504.
10. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303–332.
11. Hill AV. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol 1910; 14: iv–vii.
12. Berde CB, Sethna NF. Analgesics for the treatment of pain in children. N Engl J Med 2002; 347: 1094–1103.
13. Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1986; 1: 54–77.
14. Post TM, Freijer JI, Ploeger BA et al. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 2008; 35: 185–202.
15. Bergstrand M, Hooker AC, Wallin JE et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. J AAPS 2011; 13: 143–151.
16. Sarapa N, Britto MR, Mainka MB et al. The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor. Eur J Clin Pharmacol 2005; 61: 247–256.
17. Karim A, Laurent A, Slater ME et al. A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. J Clin Pharmacol 2001; 41: 1111–1119.
18. Stevens JC, Hines RN, Gu C et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharm Exp Ther 2003; 307: 573–582.
19. Koukouritaki SB, Manro JR, Marsh SA et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004; 308: 965–974.
20. Treluyer JM, Gueret G, Cheron G et al. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics 1997; 7: 441–452.
21. Holford NH, Ma SC, Anderson BJ. Prediction of morphine dose in humans. Pediatr Anesth 2012; 22: 209–222.
22. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24: 25–36.
23. Potts AL, Anderson BJ, Warman GR et al. Dexmedetomidine pharmacokinetics in pediatric intensive care–a pooled analysis. Pediatr Anesth 2009; 19: 1119–1129.
24. Murto K, Lamontagne C, McFaul C et al. Celecoxib pharmacogenetics and pediatric adenotonsillectomy: a double-blinded randomized controlled study. Can J Anaesth 2015; 62: 785–797.
25. Ibrahim A, Karim A, Feldman J et al. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Anesth Analg 2002; 95: 667–673.
26. Ibrahim A, Park S, Feldman J et al. Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol. Anesthesiology 2002; 96: 88–95.
27. Ibrahim AE, Feldman J, Karim A et al. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology 2003; 98: 853–861.
28. Anderson BJ, Hannam JA. Considerations when using pharmacokinetic/pharmacodynamic modeling to determine the effectiveness of simple analgesics in children. Expert Opin Drug Metab Toxicol 2015; 11: 1393–1408.
29. Li X, Zhou M, Xia Q et al. Parecoxib sodium reduces the need for opioids after tonsillectomy in children: a double-blind placebo-controlled randomized clinical trial. Can J Anaesth 2016; 63: 268–274.
30. Anderson BJ, Ralph CJ, Stewart AW et al. The dose-effect relationship for morphine and vomiting after day-stay tonsillectomy in children. Anaesth Intens Care 2000; 28: 155–160.
31. Lloyd R, Derry S, Moore RA et al. Intravenous or intramuscular parecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2009; CD004771.
32. Hannam JA, Anderson BJ, Mahadevan M et al. Postoperative analgesia using diclofenac and acetaminophen in children. Pediatr Anesth 2014; 24: 953–961.
33. Li H, Mandema J, Wada R et al. Modeling the onset and offset of dental pain relief by ibuprofen. J Clin Pharmacol 2012; 52: 89–101.
34. Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996; 60: 619–635.
35. Anderson B, Cranswick N. The placebo (I shall please)–is it so pleasing in children? Pediatr Anesth 2005; 15: 809–813.
36. Mills N, Anderson BJ, Barber C et al. Day stay pediatric tonsillectomy–a safe procedure. Int J Pediatr Otorhinolaryngol 2004; 68: 1367–1373.
37. Mahadevan M, van der Meer G, Gruber M et al. The starship children's hospital tonsillectomy: a further 10 years of experience. Laryngoscope 2016; EPub 27 April DOI 10.1002/lary.26041.
38. Riggin L, Ramakrishna J, Sommer DD et al. A 2013 updated systematic review & meta-analysis of 36 randomized controlled trials; no apparent effects of non steroidal anti-inflammatory agents on the risk of bleeding after tonsillectomy. Clin Otolaryngol 2013; 38: 115–129.
39. Cardwell M, Siviter G, Smith A. Non-steroidal anti-inflammatory drugs and perioperative bleeding in paediatric tonsillectomy. Cochrane Database Syst Rev 2005; CD003591.